Bevacizumab and Sorafenib in Treating Patients With Unresectable Stage III or Stage IV Malignant Melanoma

Clinical trial NCT00387751 · COMPLETED

Trial details

NCT number: NCT00387751
Sponsor: National Cancer Institute (NCI)
Status: COMPLETED
Phase: Phase 2
Study type: INTERVENTIONAL

Recurrent Melanoma Stage III Skin Melanoma Stage IV Skin Melanoma

Start date: 2006-08-01
Primary completion: 2009-09-01
Enrollment: 14

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.